Sirolimus 1mg/1ml oral solution

Similar documents
Tacrolimus. Information for Parents/Carers

Patient s guide for switching to

Everolimus (Afinitor )

New onset diabetes after transplant (NODAT)

Information on Azathioprine for Inflammatory Bowel Disease

Haematology Mycophenolate Mofetil Information for patients

Mycophenolate. Information for Parents/Carers

Methotrexate for inflammatory bowel disease: what you need to know

Sorafenib (Nexavar ) ( sor-af-e-nib )

For the Patient: Everolimus tablets Other names: AFINITOR

Methotrexate. Information for patients. Paediatric Rheumatology. Feedback

Intravenous anti-cancer treatment

OncoTICE powder for suspension 2-8 X 10 8 CFU Tice BCG. 1. What Oncotice is and what it is used for. 2. Before you are given Oncotice

Methotrexate in Inflammatory Bowel Disease. An information guide

Leflunomide Treatment Rheumatology Patient Information Leaflet

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

Anti-Tumor Necrosis Factor (Anti-TNF)

Oral anti-cancer treatment

Ustekinumab is used to treat moderate to severe plaque psoriasis in adults. Why have I been selected for treatment with ustekinumab?

Dabrafenib (Tafinlar )

Methotrexate Methotrexate.indd 1 9/1/16 11:40 AM

HERNOVIR 200 mg tablets

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

PACKAGE LEAFLET: INFORMATION FOR THE USER

Irbenida H 150mg/12,5mg film-coated tablets

Immunisation for pre-school children. three years and four months old

Eltrombopag (Promacta )

Imatinib (Gleevec ) ( eye-mat-eh-nib )

PATIENT INFORMATION LEAFLET EFFERFLU C IMMUNE BOOSTER. EFFERFLU C IMMUNE BOOSTER has not been evaluated by the Medicines Control

PATIENT INFORMATION LEAFLET SIMVACOR RANGE

Package leaflet: Information for the user

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]

Midostaurin (Rydapt )

Package Leaflet: Information for the User

If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment.

All medicines have risks and benefits. Your doctor has weighed the possible risks of using SALOFALK against the expected benefits.

Ibrutinib (Imbruvica )

Tacrolimus. Information for patients about using the drug Tacrolimus.

Actemra concentrate for intravenous infusion

ATORIS 10, 20, 40 mg film-coated tablets

Pain relief for your child after surgery

HYDROXYCARBAMIDE (HYDROXYUREA)

Package leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine

For the Patient: Cobimetinib tablets Other names: COTELLIC

system to help fight cancer Working with your immune

Paclitaxel (Taxol) and carboplatin

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

Eloxatin Oxaliplatin concentrated solution for injection

ALLMERCAP. Consumer Medicine Information (CMI) What is in this leaflet. What ALLMERCAP is used for. Before you take it

Some general information on hepatitis A infection is given at the end of this leaflet.

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

For the Patient: Bendamustine Other names: TREANDA

PATIENT INFORMATION LEAFLET

Why have I been selected for treatment with adalimumab?

For the Patient: UGINETEV Other Names: Treatment of advanced neuroendocrine tumours of gastrointestinal origin (Non-Functional) using Everolimus

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid

Weekly methotrexate tablets

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.

Lidocaine Hydrochloride BP 2% w/v in Lutrol F127 24% w/v Sterile Gel. Information for patients Pharmacy

PATIENT INFORMATION LEAFLET AMLOC RANGE

system to help fight cancer Working with your immune

Ibrutinib (Imbruvica )

Erlotinib (Tarceva )

Oral N-Acetyl CystieneTablets. Patient Information

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

Diphtheria, Tetanus, Pertussis, Polio, Hib and Hepatitis B vaccine for babies and children

For the Patient: PROTOCOL SMAVTMZ Other Names: Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide

Package Leaflet: Information for the User Mercaptopurine 50mg tablets 6-mercaptopurine

LIPOFEN SR 250 mg CAPSULE, HARD

Pazopanib (Votrient ) oral for renal tumours

Package Leaflet: Information for the User

PATIENT INFORMATION LEAFLET

Understanding your take home medications from the surgical ward. Information for Patients

Privigen solution for infusion

Afatinib (Giotrif ) Your treatment Your doctor has prescribed you a treatment called afatinib (Giotrif ) which is a tablet and is taken orally.

If your IBD has not been well controlled, or is flaring up quite often, methotrexate may be added to your treatment.

Bendamustine. Bendamustine. Your treatment Your doctor or nurse clinician has prescribed a course of treatment with bendamustine.

For the Patient: Ponatinib Other names: ICLUSIG

Exemestane and Everolimus

Cerebral angiography. Information for families. Great Ormond Street Hospital for Children NHS Foundation Trust

PATIENT INFORMATION LEAFLET

Lidocaine adult mouthwash 2mg in 1ml. Information for patients Pharmacy

(sunitinib malate) for Kidney Cancer

Sunitinib. Other Names: Sutent. About This Drug. Possible Side Effects. Warnings and Precautions

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

Tranexamic acid. Information for parents and carers

A guide to hydroxycarbamide (hydroxyurea)

Medication information for patients and families

For the Patient: Vemurafenib Other names: ZELBORAF

Package leaflet: Information for the user

Package leaflet: Information for the user. Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion. piperacillin / tazobactam

Perjeta Contains the active ingredient pertuzumab (rch)

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

Transcription:

Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Sirolimus 1mg/1ml oral solution You should read this information sheet in conjunction with any patient information leaflet provided by the manufacturer. However, please note that this information explains about the use of sirolimus in children and young people so may differ from the manufacturer s information. This information sheet from Great Ormond Street Hospital (GOSH) explains about sirolimus (also known as rapamycin) oral solution, how it is given and some of the possible side effects. Each person reacts differently to medicines, so your child will not necessarily suffer every side effect mentioned. If you have any questions or concerns, please ask your doctor, nurse or pharmacist, or telephone one of the contact numbers on this information sheet. What is sirolimus? Sirolimus (also known as rapamycin) is an immunosuppressant medicine, which damps down the immune system. It is most commonly used following kidney transplant to prevent the new kidney being rejected by the body. However it is now being used for other medical conditions. It is also used to treat congenital hyperinsulinism (CHI), which is characterized by inappropriate and unregulated insulin secretion from the beta-cells of the pancreas. In CHI the beta-cells release insulin inappropriately all the time and insulin secretion is not regulated by the blood glucose level (as occurs normally). Sirolimus appears to act against the beta-cells, reducing the release of insulin and stopping the beta-cells multiplying. Sirolimus is used in children with diffuse CHI and who are unresponsive to both high doses of diazoxide and octreotide and would otherwise need a major operation to remove the whole pancreas. Sirolimus oral solution comes in a strength of 1mg/1ml - that is 1ml of liquid contains 1mg of the active ingredient. Sirolimus is unlicensed for use in children and the use of sirolimus for CHI is also outside of its product licence. You can be assured that your doctor has only prescribed an unlicensed medicine because he or she thinks that the medicine will benefit your child and no licensed alternative is available. Sirolimus also contains a small amount of alcohol but the benefits of using sirolimus outweigh any risk. Sheet 1 of 5 Ref: 2014F1698 GOSH NHS Foundation Trust October 2014

How is sirolimus given? Sirolimus 1mg/1ml oral solution comes in a bottle and is a yellow colour. The oral solution sometimes develops a hazy appearance. This is not harmful and will disappear when the bottle is brought up to room temperature. The dose of sirolimus should be given consistently, either with food or without food to ensure that the same amount of active ingredient is absorbed by the body with every dose. The manufacturer recommends that each dose be diluted instructions are given below. Please discuss the volume of water or orange juice to use with your doctor. However if your child cannot tolerate this volume, it can be given undiluted but the thickness and taste of the medicine can make it difficult to give. If given undiluted, we recommend giving your child a drink of water afterwards to reduce the risk of mouth ulcers. If you are diluting the medicine, you will need: The bottle of sirolimus 1mg/1ml oral solution Syringe adapter Oral syringe with dose marked on it Glass or plastic cup Water or orange juice do not use any other liquid to mix the dose 1. Wash your hands with soap and water 2. Shake the bottle and remove the top and put to one side 3. Insert the syringe adapter into the top of the bottle leave this in the bottle when you have given the dose 4. Draw up the dose of sirolimus in the syringe provided 5. Pour half the volume of water or orange juice into a glass or plastic cup 6. Empty the syringe into the water or orange juice and mix thoroughly 7. Give to your child to drink 8. Add of the rest of the volume of water or orange juice to the cup and mix thoroughly to pick up any remaining sirolimus oral solution 9. Give to your child to drink 10. Put the top back on the bottle Dispose of the used syringe as you have been taught and wash the cup in warm, soapy water. If you need to give the dose later in the day, you can store the filled syringe for up to 24 hours at room temperature. When it is mixed with water or orange juice, you should give it to your child immediately. Sheet 2 of 5 Ref: 2014F1698 GOSH NHS Foundation Trust October 2014

Who should not use sirolimus? People with the following conditions should discuss using sirolimus with their doctor: Babies less than four weeks old Hypersensitivity to sirolimus or any of its ingredients it is not suitable for people allergic to soya or peanuts Pregnant, could be pregnant, planning to become pregnant or breastfeeding Existing liver problems Children have baseline blood tests (including urea and electrolytes, liver function, thyroid function, full blood counts, fasting cholesterol and triglycerides) before starting treatment with sirolimus and then at regular intervals during treatment. Sirolimus blood level will be monitored every four weeks. If the dose or formulation changes, this should be repeated seven days after the change has been introduced. What are the side effects? Possible fever, headache, fatigue, stomach pain, diarrhoea, constipation, nausea, low red blood cells, low blood platelets, increased fat in the blood (cholesterol and/or triglycerides), low blood potassium, low blood phosphorus, slow healing (if your child has a high blood sugar level), rapid heart rate, mouth sores, fluid collection in the abdomen, kidney problems, protein in the urine, reduced number of infection-fighting cells in the blood (white blood cells), abnormal tests of liver function, rash. Sirolimus can reduce the body s own defence mechanisms and consequently the body will not be as good at fighting infections. So, infections can be caught more often than usual, such as infections of the skin, mouth, stomach and intestines, lungs and urinary tract. Uncommon: Fluid collection in the sac around the heart, inflammation of the pancreas, blood clots, cancer of the lymph tissue (lymphoma), bleeding from the lung. Rare: Protein build-up in the air sacs of the lungs that may interfere with breathing, too much fluid collecting in the tissues due to irregular lymph function, serious allergic reactions As with all medications, there can be allergic reactions Signs of a mild allergic reaction include skin rashes and itching, high temperature, shivering, redness of the face, a feeling of dizziness or a headache. If you see any of these signs, please report them to a doctor or nurse. Signs of a severe allergic reaction include any of the above, as well as shortness of breath or chest pain. If you are in hospital and your child shows signs of a severe allergic reaction, call a doctor or nurse immediately. If you are at home and your child shows signs of a severe allergic reaction, call an ambulance immediately. If your child has a severe reaction to sirolimus, the subsequent treatment will probably be changed. Sheet 3 of 5 Ref: 2014F1698 GOSH NHS Foundation Trust October 2014

Sirolimus and interactions with other medicines Some medicines can react with sirolimus, altering how well it works. Always check with your doctor or pharmacist before giving your child any other medicine, including medicines on prescription from your family doctor (GP), medicines bought from a pharmacy (chemist) or any herbal or complementary medicines. The following medicines are known to react with sirolimus: Other immunosuppressant medicines Certain antibiotics or antifungal medicines Anti-hypertension medicines Anti-epilepsy medicines Certain anti-ulcer medicines Sirolimus reacts with grapefruit so should never be mixed with grapefruit juice drinks (including Sunny Delight ) or grapefruit should not be eaten during treatment with sirolimus. Important information Keep medicines in a safe place where children cannot reach them. Sirolimus oral solution should be kept in its original packaging in the refrigerator. When you have drawn a dose up into the syringe, this can be stored at room temperature for up to 24 hours. When it is mixed with water or orange juice, you should give it to your child immediately. If your child vomits immediately after a dose of sirolimus, repeat the dose. Otherwise do not give a second dose. Please ring your doctor or nurse to inform them and for further advice. Your child should NOT have any live vaccinations such as MMR, oral polio, chicken pox or BCG while taking sirolimus. Inactivated or killed vaccines such as influenza/flu, meningitis C, pneumococcal, hepatitis, Hib, tetanus, diphtheria, whooping cough/pertussis and the killed version of the polio immunisation are permitted. If you have other children who need vaccines while your child is taking sirolimus, they should have these as normal, but they should also receive the killed or inactivated polio vaccine. If you have any questions about vaccines and immunisations, please ask your doctor. Exposure to sunlight and UV light should be limited by covering the skin with clothing and using sunscreen with a high protection factor due to an increased risk of skin cancer. If your doctor decided to stop treatment with sirolimus, return any unused oral solution to the pharmacist. Do not flush it down the toilet or throw it away. Sheet 4 of 5 Ref: 2014F1698 GOSH NHS Foundation Trust October 2014

Notes Useful numbers GOSH switchboard: 020 7405 9200 Pharmacy Medicines Information: 020 7829 8608 Monday to Friday from 9am to 5pm Congenital Nurse Specialists for Hyperinsulinism: ext 0360 or bleep 1016 Out of hours: 020 7405 9200 and ask for the on call doctor for endocrinology Compiled by the Congenital Hyperinsulinism team and Pharmacy department in collaboration with the Child and Family Information Group Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH www.gosh.nhs.uk Sheet 5 of 5 Ref: 2014F1698 GOSH NHS Foundation Trust October 2014